H

Hospital Universitario Puerta de Hierro Majadahonda | Departamento de Oncologia Medica

Research site
(Unclaimed)
Location
Calle Manuel de Falla 1, Madrid, Madrid, Spain
Site insights

Top conditions

Colorectal Cancer (3 trials)

Heart Failure (2 trials)

Fatty Liver (2 trials)

Lung Cancer (2 trials)

Breast Cancer (2 trials)

Top treatments

Bevacizumab
Ziltivekimab
Olaparib
Obeticholic Acid
Methylprednisolone
Pralatrexate
THR-149
Momelotinib
Paclitaxel
Atezolizumab

Parent organization

This site is a part of Hospital Universitario Puerta de Hierro Majadahonda

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 36
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if th...

Active, not recruiting
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: NNC6019-0001
Drug: Placebo (NNC6019-0001)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

To assess:efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification,...

Enrolling
Glioblastoma Multiforme
Brain Tumor
Drug: APL-101 Oral Capsules

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Drug: Bemarituzumab
Drug: Placebo

The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelo...

Active, not recruiting
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Drug: MMB

This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA...

Active, not recruiting
Osteoarthritis, Knee
Device: nSTRIDE APS
Device: Synvisc-One

The purpose of this study is to collect long-term safety and tolerability data for aficamten (CK-3773274)

Invitation-only
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Drug: CK-3773274 (5 - 20 mg)

Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr...

Active, not recruiting
Advanced Breast Cancer
Drug: Vinorelbine
Drug: Alpelisib

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafe...

Enrolling
Metastatic Colorectal Cancer
Drug: ZN-c3
Drug: Cetuximab

Trial sponsors

Novo Nordisk logo

Novo Nordisk (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems